{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:37:15Z","timestamp":1765294635992},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s53675","type":"journal-article","created":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T01:53:10Z","timestamp":1392256390000},"page":"87","source":"Crossref","is-referenced-by-count":2,"title":["Active axial spondyloarthritis: potential role of certolizumab pegol"],"prefix":"10.2147","author":[{"given":"Sriya","family":"Ranatunga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,2]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=18970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:14:01Z","timestamp":1477865641000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/active-axial-spondyloarthritis-potential-role-of-certolizumab-pegol-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s53675","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}